Role of Sotagliflozin in Managing Heart Failure in Diabetes`
DOI:
https://doi.org/10.47957/ijciar.v7i2.178Keywords:
Sotagliflozin (LX4211), SGLT1 and SGLT2 inhibitors, pharmacokineticsAbstract
A persistent illness called heart failure lowers heart function. Patients with chronic illnesses like diabetes and hypertension are especially vulnerable to the damage caused by this failure, which can put strain on other organs. Heart failure is more common in those with diabetes. An oral antidiabetic medication is called sotagliflozin. A dual sodium drug used to treat heart failure, sotagliflozin shows great promise. An important new family of drugs being developed to treat diabetes is the sodium-dependent glucose transporter 2 (SGLT2) inhibitors. The goal of high selectivity for the SGLT2 protein in comparison to the SGLT1 protein has guided the development of SGLT2 inhibitors. Treating diabetes through complementary insulin-independent pathways could be made possible by combining SGLT1 and SGLT2 inhibition in a single drug. Consequently, a dual SGLT1 and SGLT2 inhibitor called sotagliflozin (LX4211) has been developed. A significant reduction in postprandial glucose, an increase in glucagon-like peptide 1, and a moderate excretion of glucose in the urine are the distinguishing clinical aspects of dual inhibitors of SGLT1 and SGLT2. The usage of sotagliflozin in the treatment of diabetes may be affected clinically by these characteristics.
Downloads
References
Nagoshi T, Yoshimura M, MC Rosano G, D Lopaschuk G, Mochizuki S. Optimization of cardiac metabolism in heart failure. Current pharmaceutical design. 2011 Dec 1;17(35):3846-53. https://doi.org/10.2174/138161211798357773. DOI: https://doi.org/10.2174/138161211798357773
Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. The American journal of cardiology. 2006 Sep 4;98(5):14-8. https://pubmed.ncbi.nlm.nih.gov/16931201/ DOI: https://doi.org/10.1016/j.amjcard.2006.07.004
Kolapudi RK, Kapudasi J, Koppula SB, Chandu B. Stem Cells Treatment for the Future Heart Diseases. Drug Invention Today. 2012 Jun 1;4(6).
Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiological reviews. 2011 Apr;91(2):733-94. http://doi.org/10.1186/s12933-019-0828- DOI: https://doi.org/10.1152/physrev.00055.2009
Li Y, Shi Z, Chen L, Zheng S, Li S, Xu B, Liu Z, Liu J, Deng C, Ye F. Discovery of a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor (HSK0935) for the treatment of type 2 diabetes. Journal of Medicinal Chemistry. 2017 May 25;60(10):4173-84. http://doi.org/10.1186/s12933-019-0828- DOI: https://doi.org/10.1021/acs.jmedchem.6b01818
Chu KF, Song JS, Chen CT, Yeh TK, Hsieh TC, Huang CY, Wang MH, Wu SH, Yao CH, Chao YS, Lee JC. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors. Bioorganic chemistry. 2019 Mar 1;83:520-5. DOI: https://doi.org/10.1016/j.bioorg.2018.11.006
Yuan MC, Yeh TK, Chen CT, Song JS, Huang YC, Hsieh TC, Huang CY, Huang YL, Wang MH, Wu SH, Yao CH. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. European Journal of Medicinal Chemistry. 2018 Jan 1;143:611-20. DOI: https://doi.org/10.1016/j.ejmech.2017.11.019
Ng WL. Synthetic Studies towards Carbocyclic Analogues of SGLT2 Inhibitors. The Chinese University of Hong Kong (Hong Kong); 2014.
Mezza T, Muscogiuri G, Sorice GP, Clemente G, Hu J, Pontecorvi A, Holst JJ, Giaccari A, Kulkarni RN. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes. 2014 Mar 1;63(3):994-1007. DOI: https://doi.org/10.2337/db13-1013
Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A. Improved glycemic control in mice lacking Sglt1 and Sglt2. American Journal of Physiology-Endocrinology and Metabolism. 2013 Jan 15;304(2):E117-30. DOI: https://doi.org/10.1152/ajpendo.00439.2012
Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diabetes and Vascular Disease Research. 2015 Mar;12(2):101-10. DOI: https://doi.org/10.1177/1479164114563304
Patel K, Carbone A. Sodium-glucose cotransporters as potential therapeutic targets in patients with type 1 diabetes mellitus: an update on phase 3 clinical trial data. Annals of Pharmacotherapy. 2019 Dec;53(12):1227-37. DOI: https://doi.org/10.1177/1060028019859323
Long A, Salvo M. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure. Annals of Pharmacotherapy. 2023 Nov 28:10600280231211179. DOI: https://doi.org/10.1177/10600280231211179
Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes and Vascular Disease Research. 2015 Mar;12(2):78-89. DOI: https://doi.org/10.1177/1479164114561992
Published
How to Cite
Issue
Section
Citations
This work is licensed under a Creative Commons Attribution 4.0 International License.
